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Abstract
Background: The relationship between radiation exposure for treatment of cancer and
occurrence of a second primary cancer at the irradiated site is well known. This phenomenon is
however rare in prostate.
Case presentation: A 75-year-old farmer was treated for rectal cancer with preoperative 45 Gy
of radiotherapy and abdominoperineal resection. Four years later he developed symptoms of
bladder outlet obstruction and acute urinary retention. He underwent a transurethral resection of
the prostate. Histological examination of the removed prostate tissue and immunohistochemistry
revealed it to be a poorly differentiated sarcoma.
Conclusion: We believe this to be the first reported case of radiation-induced sarcoma following
radiotherapy treatment for rectal cancer. Since radiotherapy plays a pivotal role in the
contemporary treatment of rectal adenocarcinoma, it is relevant to be aware of the potential long-
term carcinogenic complications of radiotherapy of the pelvis.
Background
Many cancer patients will receive radiation in the course
of their cancer treatment [1]. With this increased use of
adjuvant radiation, radiation induced cancer has become
a well-recognized phenomenon. The relationship
between radiation exposure and excess cancer incidence
has been well documented for a wide variety of carcino-
mas and sarcomas in various sites.
Soft tissue sarcoma is a well-recognized complication fol-
lowing radiation exposure. The risk is thought to be 1% of
patients [2]. Current modalities target tumour precisely
but actually increase the overall amount of normal tissue
exposed to low to moderate-dose ionising radiation [3].
As increasing numbers of patients with early-stage cancer
are treated with radiation and survive longer, it seems
likely that incidence of radiotherapy (RT)-induced soft tis-
sue sarcoma will increase [4].
There is a latency period between radiation and the occur-
rence of soft tissue sarcoma. The cut-off is thought to be at
least four years following radiation treatment. This latency
period is necessary to differentiate a RT-induced sarcoma
from a second primary that may predate the radiation
treatment because no accurate molecular or pathologic
markers exist. Thus any spontaneous sarcoma that
appears in a radiation field is considered to be a radiation-
induced malignancy [5]. Current estimates suggest that
RT-induced sarcomas account for between 2.5 to 5.5% of
all sarcomas [5,6].
Pelvic radiation for cancers other than rectal cancer has
been implicated in the development of variety of soft tis-
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osteogenic sarcoma and soft tissue sarcomas [8] such as
prostatic carcinosarcoma [9], leiomyosarcoma of the rec-
tum [10], and uterine sarcoma [11]. In this case report we
present what we believe to be the first case of prostate sar-
coma following preoperative neoadjuvant radiation for
cancer of the rectum.
Case presentation
A previously healthy 75-year-old farmer presented with a
two-month history of rectal bleeding. He also gave a his-
tory of mild tenesmus and a feeling of faecal urgency; he
had been otherwise well. Rigid sigmoidoscopy revealed a
rectal tumour at 10 cm from the anal verge situated on the
anterior wall of the rectum. Biopsy of the lesion showed a
moderately differentiated adenocarcinoma. Colonoscopy
showed no further lesions in the colon. A magnetic reso-
nance imaging (MRI) of the rectum showed that the
tumour was extensive and abutted the fascia propria on
the back of the prostate. It also appeared to involve the
levator ani muscles. A staging CT scan showed no evi-
dence of liver or lung metastases. He underwent preoper-
ative radiotherapy in the form of fractionated doses of 45
Gy given five days a week for five weeks.
Six weeks after radiotherapy he underwent an ultra low
Hartmann's resection (Abdomino-perineal resection)
with a permanent colostomy. Pathological examination
of the removed rectum showed a T3 tumour with no
lymph node involvement. He recovered well from surgery
and managed his colostomy with no difficulty. Regular
clinic follow-up was conducted and he continued to be
well.
Four years later he developed symptoms of bladder outlet
obstruction and acute urinary retention. He underwent a
transurethral resection of the prostate. Histological exam-
ination of the removed prostate tissue showed prostate
tissue and an anaplastic malignant tumour extensively
infiltrating over 50% of the prostate tissue. Prominent
within the tumour were large multinucleated cells with
frequent, atypical, mitotic figures with extensive coagulat-
ive necrosis.
There was no evidence of gland formation within the
tumour and specific features of colorectal carcinoma were
not identified. Immunostaining showed the tumour was
negative for epithelial markers cytokeratin 7, cytokeratin
20, cytokeratin 34B12, CEA and PSA. The tumour was also
negative for the melanoma marker S100, the lymphocyte
marker LCA, the muscle marker MSA, and the syncytiotro-
phoblast marker Beta HCG. The histological and immu-
nohistochemical features were therefore those of a poorly
differentiated sarcoma.
After the confirmation of sarcoma on tissue examination
CT scan of the abdomen was performed. The scan (Figure
1) showed an enlarged and heterogenous prostate, with
central fluid density. There was no local or distant aden-
opathy.
Discussion
Rectal cancer is commonly treated with combination of
surgical resection and radiotherapy, which is adminis-
tered either before or after surgery [11,12]. The occurrence
of prostatic sarcoma has not been reported before.
The diagnosis of post radiation sarcoma (PRS) is generally
based on the following criteria:
• The histological features of the original lesion and PRS
are completely different.
• PRS is located within the field of irradiation.
• Patients with cancer syndromes such as Li-Fraumeni and
Rothmund-Thomson are excluded.
• The latent period (period between initiation of radio-
therapy and histological diagnosis of second neoplasm) is
more than 4 years. Although arbitrary given the wide age
range reported in the literature (4–55 y), a period of 4
years generally has been accepted as being the lower limit
for the latent period.
Medline was searched between 1966–2007 for rectal can-
cer, radiation therapy, and sarcoma, all as Medical Subject
Headings. The relevant articles were reviewed for risk of
carcinogenesis, treatment and prognosis of radiation-
induced sarcoma following were retrieved. Marmion et al.,
have reported the development of a uterine carcinosar-
coma more than 9 years after preoperative radiotherapy
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of giant cell malignant fibrous histiocytoma in the pelvis
9 years following radiotherapy for rectal cancer. On the
other hand a case of rectal adenocarcinoma has been
described in a 9-year-old child following radiation treat-
ment of pelvic rhabdomyosarcoma [14].
Radiation-induced sarcomas are thought to be aggressive,
high-grade tumours, often with a poor prognosis. In a
large series from the Memorial Sloan-Kettering cancer cen-
tre 90% of patients were able to undergo resection for cur-
ative intent; however, 46% of patients had either a gross
or microscopically positive resection margin despite the
fact that the majority of these tumours were less than 5 cm
in diameter [5]. From the same group 80% of patients
who had tumour resection had high-grade tumours,
resulting in a 5-year survival of 34% for this subgroup of
patients. Radiation induced sarcomas tend to be diffuse
and infiltrate along tissue planes that have been made
indistinct by the effect of previous radiation. Positive mar-
gins result in a 50% reduction in survival. This suggests
aggressive and wide excision to achieve complete curative
resection is required to improve the chances of long sur-
vival. Survival in radiation-induced sarcoma is generally
worse than other sarcomas [15-18].
Radiation-induced sarcoma remains uncommon and
arises in 0.035 to 0.2% of all irradiated patients [19]. The
most common histological subtypes of radiation-induced
sarcomas are osteogenic, malignant fibrous histiocytoma,
angio- and lymphangiosarcoma and spindle cell sarcoma
[19,20]. Despite the low incidence of radiation-induced
sarcoma, it is expected to be seen more frequently, due to
an increased life expectancy with progressively improved
survival in cancer patients as a result of increased effective-
ness of cancer therapy and better treatment regimes; how-
ever the dose-effect relationship between radiation and
sarcoma is controversial [19-23]. Neither a minimum of
cumulative radiation dose nor a correlation between
modality of radiation and the incidence of radiation-
induced sarcomas is reported in the medical literature, but
it is generally agreed that high radiation dose is needed for
development of sarcoma [24]. A radiation dose-response
relationship has been demonstrated for all sarcomas and,
for the first time in humans, for soft tissue sarcomas.
Several mechanisms by which radiation may induce
genetic changes leading to malignant transformation have
been proposed, but the exact development of radiation-
induced cancer is still unclear. The loss of heterozygosity
in directly radiated cell nuclei activate mutational occur-
rences in tumour suppressor genes resulting in malignant
degeneration. Furthermore, genetic mutations may also
be induced by cytoplasmic irradiation and the release of
cytokines. Therefore, important genetic effects can also be
observed in cells that did not directly receive nuclear radi-
ation [24].
Conclusion
Thus long-term follow-up is important for patients who
have been treated with radiotherapy. Any suspicious
lesion should be thoroughly assessed with imaging and
tissue sampling to identify the nature of the lesion. If the
lesion proves to be sarcoma the treatment of choice for
radiation-induced sarcomas is surgical resection with clear
gross and microscopic margins. Chemotherapy for radia-
tion-induced sarcoma is not proven to result in prolonged
survival [5].
While we have not established a conclusive relationship
between the sarcoma of the prostate and the previous
radiotherapy the association between the two seems to be
more than coincidental and we wait with interest further
reports from other institutions.
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